Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
PGEN Price Action
Last 7 days
-4.3%
Last 30 days
-13.9%
Last 90 days
-21.5%
Trailing 12 Months
316.3%
PGEN RSI Chart
PGEN Valuation
PGEN Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
PGEN Fundamentals
PGEN Revenue
PGEN Earnings
PGEN Profitability
PGEN Investor Care
PGEN Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 23.2M | 22.1M | 0 | 0 |
| 2022 | 16.3M | 15.4M | 28.8M | 26.9M |
| 2021 | 97.9M | 71.2M | 51.0M | 35.3M |
| 2020 | 98.0M | 95.6M | 100.8M | 103.2M |
| 2019 | 134.1M | 121.7M | 107.5M | 90.7M |
| 2018 | 217.1M | 208.0M | 194.4M | 151.2M |
| 2017 | 201.2M | 203.2M | 200.2M | 231.2M |
| 2016 | 183.2M | 190.8M | 186.4M | 190.9M |
| 2015 | 97.9M | 131.0M | 163.2M | 173.6M |
| 2014 | 27.7M | 32.8M | 48.0M | 71.9M |
| 2013 | 16.1M | 20.1M | 23.2M | 23.8M |
| 2012 | 9.5M | 10.9M | 12.3M | 13.8M |
| 2011 | 0 | 0 | 0 | 8.0M |
Get all data in R, Python etc through our Historical Stock Data APIs
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
| CEO | Dr. Helen Sabzevari MPH, Ph.D. |
|---|---|
| WEBSITE | https://precigen.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 209 |
